49 related articles for article (PubMed ID: 38503522)
1. Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a report of four cases.
Wang Q; Hu Y; Gao L; Zhang S; Lu J; Li B; Li J; Yao Y; Cheng S; Xiao P; Hu S
Ann Hematol; 2024 May; ():. PubMed ID: 38802593
[TBL] [Abstract][Full Text] [Related]
2. The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Zhang Y; Feng S
Leuk Res; 2021 Oct; 109():106647. PubMed ID: 34325192
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia.
Xue S; Sun HP; Huang XB; Chen X; Wang T; Ma W; Tian Y; Pan ZL; Li LH; Zhang L; Liu HX; Cao XY
Int J Hematol; 2024 May; 119(5):564-572. PubMed ID: 38441775
[TBL] [Abstract][Full Text] [Related]
4. [Clinical analysis of allogeneic hematopoietic stem cell transplantation for seven cases of acute myeloid leukemia with BCR::ABL1 fusion].
Hao MZ; Zhao XL; Zhang XY; Shi YY; Gong M; Zhang LN; Chen SL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):995-1000. PubMed ID: 38503522
[No Abstract] [Full Text] [Related]
5. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
[TBL] [Abstract][Full Text] [Related]
6. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with
Mizuno S; Takami A; Kawamura K; Harada K; Masayoshi M; Yano S; Ito A; Ozawa Y; Ouchi F; Ashida T; Nawa Y; Ichinohe T; Fukuda T; Atsuta Y; Yanada M
EJHaem; 2024 Apr; 5(2):369-378. PubMed ID: 38633128
[No Abstract] [Full Text] [Related]
8. Prognostic significance of a normal karyotype in adult patients with BCR-ABL1-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era.
Shi T; Wang H; Xie M; Li X; Zhu L; Ye X
Clinics (Sao Paulo); 2020; 75():e2011. PubMed ID: 33206758
[TBL] [Abstract][Full Text] [Related]
9. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
[TBL] [Abstract][Full Text] [Related]
10. Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome-positive acute myeloid leukemia: A case report.
Huang SM; Tao T; Wan CL; Wu TM; Cao HY; Qiu Y; Shen XD; Wang BR; Ge SS; Li YY; Zhang TT; Wu B; Xue SL
Clin Case Rep; 2023 Jan; 11(1):e6688. PubMed ID: 36619491
[TBL] [Abstract][Full Text] [Related]
11. Molecular genetic characterization of Philadelphia chromosome-positive acute myeloid leukemia.
Zhou Q; Zhao D; Eladl E; Capo-Chichi JM; Kim DDH; Chang H
Leuk Res; 2023 Jan; 124():107002. PubMed ID: 36563650
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
Döhner H; Wei AH; Appelbaum FR; Craddock C; DiNardo CD; Dombret H; Ebert BL; Fenaux P; Godley LA; Hasserjian RP; Larson RA; Levine RL; Miyazaki Y; Niederwieser D; Ossenkoppele G; Röllig C; Sierra J; Stein EM; Tallman MS; Tien HF; Wang J; Wierzbowska A; Löwenberg B
Blood; 2022 Sep; 140(12):1345-1377. PubMed ID: 35797463
[TBL] [Abstract][Full Text] [Related]
13. AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax.
Low SK; Nanua S; Patel M; Renteria AS
Leuk Res Rep; 2022; 17():100333. PubMed ID: 35782581
[TBL] [Abstract][Full Text] [Related]
14. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
Khoury JD; Solary E; Abla O; Akkari Y; Alaggio R; Apperley JF; Bejar R; Berti E; Busque L; Chan JKC; Chen W; Chen X; Chng WJ; Choi JK; Colmenero I; Coupland SE; Cross NCP; De Jong D; Elghetany MT; Takahashi E; Emile JF; Ferry J; Fogelstrand L; Fontenay M; Germing U; Gujral S; Haferlach T; Harrison C; Hodge JC; Hu S; Jansen JH; Kanagal-Shamanna R; Kantarjian HM; Kratz CP; Li XQ; Lim MS; Loeb K; Loghavi S; Marcogliese A; Meshinchi S; Michaels P; Naresh KN; Natkunam Y; Nejati R; Ott G; Padron E; Patel KP; Patkar N; Picarsic J; Platzbecker U; Roberts I; Schuh A; Sewell W; Siebert R; Tembhare P; Tyner J; Verstovsek S; Wang W; Wood B; Xiao W; Yeung C; Hochhaus A
Leukemia; 2022 Jul; 36(7):1703-1719. PubMed ID: 35732831
[TBL] [Abstract][Full Text] [Related]
15. Blast and accelerated phase CML: room for improvement.
How J; Venkataraman V; Hobbs GS
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):122-128. PubMed ID: 34889372
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
